MyD88 Antibody
- Known as:
- MyD88 Antibody
- Catalog number:
- 3244R-100
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biovis
- Gene target:
- MyD88 Antibody
Related genes to: MyD88 Antibody
- Gene:
- MYD88 NIH gene
- Name:
- MYD88 innate immune signal transduction adaptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 3p22.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-12-23
- Date modifiied:
- 2019-04-23
Related products to: MyD88 Antibody
Related articles to: MyD88 Antibody
- Toll-like receptor 2/1 (TLR2/1) heterodimers detect triacylated lipoproteins. Although TLR2/1 complexes localize to both the plasma membrane and endosome, the functional contributions of compartment-specific signaling are not completely defined. A common human TLR1 polymorphism (rs5743618), at which one allele substitutes isoleucine for serine adjacent to the transmembrane domain, restricts TLR1 intracellularly and is associated with an increased risk of antibiotic-refractory Lyme arthritis. This mis-localization provides a model to examine how receptor positioning influences downstream signaling. Here, we investigated the rs5743618 polymorphism's effects on TLR1 localization and compartment-specific NF-κB activation. Using a CD14+ TLR2+ HEK cell reporter system that enables transient expression of both allelic variants, we confirmed that the polymorphism is excluded from the cell surface and retained intracellularly, whereas the ancestral allele localizes to both compartments. Functionally, the ancestral allele signaled from both compartments, while the derived allele signaled exclusively from endosomes. Spatially restricted signaling exhibited influence on IkBα degradation and NF-κB activation compared with the ancestral allele. This activation was dependent on MyD88 localized at ligand-containing endosomes, establishing a role for this adapter in intracellular TLR2/1 signaling. These findings provide insight into how this common polymorphism impacts inflammatory outcomes. - Source: PubMed
Publication date: 2026/10/05
Wells Christopher CBourgeois Jeffrey SWilliams Morgan AStrle KlemenHu Linden TPetnicki-Ocwieja Tanja - Macrophages are highly plastic immune cells with tumor-homing capacity and immunomodulatory functions, making macrophage-based nanoplatforms attractive for cancer immunotherapy. Macrophage-based nanoplatforms include macrophage-derived extracellular vesicles (EVs), macrophage membrane-coated nanoparticles, and live macrophage carriers. The platforms combine the biological properties of macrophages with the advantages offered by nanocarriers to achieve targeted delivery and immune regulation. Beyond serving as delivery vehicles, macrophages can be therapeutically reprogrammed through strategies such as CD47-SIRPα blockade and TLR7/MyD88 pathway activation to enhance antitumor immunity. Despite promising preclinical outcomes, clinical translation of macrophage-based Biomimetic nano-drug delivery systems (BNDDS) remains challenging due to cytokine release syndrome risk, scalable manufacturing limitations, and species differences between animal models and human immunity. The review provides insights into the development and clinical translation of macrophage-based BNDDS for cancer therapy. - Source: PubMed
Publication date: 2026/09/30
Li XiuguoYu YibinXie YanHe PengChen YunlongGuo ZhaomingYu ShimeiZhang LingChen Fen - The flowers of Hylocereus undatus (Haw.) Britton & Rose (HUF), commonly known as "Jianhua" or "Bawanghua", represent a well-known medicinal-edible plant in South China. In folk practice, HUF is traditionally applied to ameliorate respiratory disorders, including cough, sore throat and other influenza-like symptoms. Cumulative pharmacological evidence has demonstrated that HUF extracts possess anti-inflammatory and immunomodulatory activities. Nevertheless, its protective effects against influenza infection remain largely unclarified, with the underlying molecular mechanisms yet to be elucidated. - Source: PubMed
Publication date: 2026/10/03
Wang XinJiang LizhouLiang FengPeng XiaorongLuo YananJin BoTran QuangminhLi DongdongLuo Zhuo - Diabetic retinopathy (DR) is a metabolic eye disease closely linked to inflammation and oxidative stress, potentially causing vision decline or blindness. Scutellarin (SCU), a major flavonoid extracted from Erigeron breviscapus, possesses anti-inflammatory and antioxidant properties; however, its protective mechanisms against retinal Müller cell (RMC) injury in DR remain unclear. - Source: PubMed
Publication date: 2026/09/18
Tang YunhuaDing ShanPeng WenyanWu MeichuMao YongqiYang WenxinLi XiaoyangZhang Fuwen - Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen-presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self-Assembling Peptide-Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist 1V209 through site-selective lysine conjugation. Synthesized by Fmoc solid-phase peptide synthesis, SaPAC conjugates self-assemble into cationic nanoparticles with hydrodynamic diameters of approximately 100-200 nm. Compared with unconjugated self-assembling peptide nanoparticles mixed with soluble adjuvant, SaPAC nanoparticles enhanced lymphatic drainage and antigen persistence in draining lymph nodes. Mechanistically, SaPAC activated the TLR7-MyD88 axis, promoted plasmacytoid dendritic cell and macrophage recruitment, drove APC maturation (CD80CD86), and enhanced MHC-I cross-presentation to amplify antigen-specific CD8+ T-cell priming. Therapeutically, SaPAC monotherapy suppressed tumor growth in B16-OVA melanoma and MB49 bladder carcinoma models by increasing intratumoral infiltration of activated CD8+ T cells and NK cells. In an orthotopic 4T1 triple-negative breast cancer model, multivalent SaPAC vaccination synergized with anti-PD-1 blockade and achieved durable tumor suppression comparable to the Poly(I:C)-adjuvanted benchmark without detectable systemic toxicity. Collectively, SaPAC represents a chemically defined platform that bridges innate and adaptive anti-tumor immunity. - Source: PubMed
Publication date: 2026/10/02
Wu Yang-FanHu Jing-ChuHu Ye-FanLi Wen-JunRong LiLi Ren-HaoYao YuanHu LehanWang Xiao-LeiZhang Bao-ZhongLu YichengChow Shing-FungSu CanhuiYau ThomasChung Clive Yik-ShamHuang Jian-Dong